Format

Send to

Choose Destination
Sex Med Rev. 2019 Jan;7(1):84-94. doi: 10.1016/j.sxmr.2018.09.006. Epub 2018 Nov 30.

Selective Androgen Receptor Modulators: Current Knowledge and Clinical Applications.

Author information

1
Baylor College of Medicine, Houston, TX, USA.
2
Scott Department of Urology, Baylor College of Medicine, Houston, TX, USA.
3
Urology Associates, Denver, CO, USA.
4
Brady Urological Institute, Johns Hopkins School of Medicine, Baltimore, MD, USA.
5
Scott Department of Urology, Baylor College of Medicine, Houston, TX, USA; Urology Associates, Denver, CO, USA.
6
Scott Department of Urology, Baylor College of Medicine, Houston, TX, USA; Center for Reproductive Medicine, Baylor College of Medicine, Houston, TX, USA. Electronic address: alexander.pastuszak@hsc.utah.edu.

Abstract

INTRODUCTION:

Selective androgen receptor modulators (SARMs) differentially bind to androgen receptors depending on each SARM's chemical structure. As a result, SARMs result in anabolic cellular activity while avoiding many of the side effects of currently available anabolic steroids. SARMs have been studied in the treatment of breast cancer and cachexia and have also been used as performance-enhancing agents. Here, we evaluate and summarize the current literature on SARMs.

AIM:

To present the background, mechanisms, current and potential clinical applications, as well as risks and benefits of SARMs.

METHODS:

A literature review was performed in MEDLINE using the terms selective androgen receptor modulator, hypogonadism, cachexia, breast cancer, benign prostatic hyperplasia, libido, and lean muscle mass. Both basic research and clinical studies were included.

MAIN OUTCOME MEASURE:

To complete a review of peer-reviewed literature.

RESULTS:

Although there are currently no U.S. Food and Drug Agency-approved indications for SARMs, investigators are exploring the potential uses for these compounds. Basic research has focused on the pharmacokinetics and pharmacodynamics of these agents, demonstrating good availability with a paucity of drug interactions. Early clinical studies have demonstrated potential uses for SARMs in the treatment of cancer-related cachexia, benign prostatic hyperplasia (BPH), hypogonadism, and breast cancer, with positive results.

CONCLUSION:

SARMs have numerous possible clinical applications, with promise for the safe use in the treatment of cachexia, BPH, hypogonadism, breast cancer, and prostate cancer. Solomon ZJ, Mirabal JR, Mazur DJ, et al. Selective Androgen Receptor Modulators: Current Knowledge and Clinical Applications. Sex Med Rev 2019;7:84-94.

KEYWORDS:

Androgens; Drug-Related Side Effects and Adverse Reactions; Hypogonadism; Selective Androgen Receptor Modulators

PMID:
30503797
PMCID:
PMC6326857
[Available on 2020-01-01]
DOI:
10.1016/j.sxmr.2018.09.006
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center